Thyrocare Technologies Ltd - 539871 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report27/05/2019 3 Name of the Certifying Firm V. SURESH 4 Name of the Certifying Individual MR. V. SURESH 5Membership TypeFCS 6 Membership Number 2969 7 CP No. 6032 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you about the following forthcoming Analyst Meetings: i) Meeting with the representative(s) of CWC Advisors, at 02.00 P.M. on Tuesday, May 28, 2019 at the Corporate Office of the Company. ii) Meeting with the representative(s) of Mirabilis Investment Trust, at 04.00 P.M. on Wednesday, May 29, 2019 at the Corporate Office of the Company. ii) Participation of our representative(s) at 'Trinity India- 2019' Organized by Batlivala & Karani Securities India Pvt. Ltd. at Hotel Trident, BKC on Friday, May 31, 2019 from 10.00 A.M., where representatives of various fund houses would be met. Please note that these are subject to any last minute changes. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representative(s) of SAIF Partners would be having a Con-call with us by 3.00 P.M. today (Thursday, May 23, 2019). Please note that this is subject to any last minute changes. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representative(s) of Anived Portfolio Managers Private Limited, would be having a meeting with us at 2.00 P.M. on Wednesday, May 22, 2019 at the Corporate Office of the Company. Thyrocare Technologies Ltd - 539871 - Commencement Of Operation On Tender Awarded By Municipal Corporation Of Greater Mumbai For Availing Laboratory Investigative Services 'Aapli Chikitsa'.
We wish to intimate that we had participated in the tender floated by Municipal Corporation of Greater Mumbai (the 'MCGM') for outsourcing of laboratory investigative services 'Aapli Chikitsa', and we have now received a letter from MCGM informing us that our tender has been accepted by them. We have been authorized to provide laboratory investigative services 'Aapli Chikitsa' over a period of 4 years from the commencement of operations, to the MCGM affiliated hospitals and clinics in Western Suburban Zone and City Zone of Mumbai. The total contract cost of the tender to be executed over the period of 4 years is Rs. 532.27 million, with an assurance of about 60% of total samples test per year. We have since complied with the terms and conditions and are poised to commence the operation on tender awarded by Municipal Corporation of Greater Mumbai for availing laboratory investigative services 'Aapli Chikitsa' within next 30 days. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Meeting Updates
Sub: Update on Outcome of Board Meeting held on 18-05-2019 Please refer to our letter dated 18th May 2019, intimating about the decisions taken at the Board Meeting held on 18-05-2019. We wish to add that at the above Board Meeting, when the Auditors pointed out the impairment of investment in Nueclear Healthcare Limited (NHL), the wholly owned subsidiary, Dr. A. Velumani, Chairman, Managing Director & CEO has offered to buy the entire shareholding of the Company in NHL at the current investment value of Rs. 194.67 crores to ensure that there is no loss to the public shareholders. However, all required formalities will be complied with by the Company for such a transaction. We were waiting for the concurrence from the Auditors to intimate this and hence the delay. Thyrocare Technologies Ltd - 539871 - Subject: Corrigendum - Audited Financial Results For The Year Ended March 31, 2019 Along With Fourth Quarter Results.- Minor Error Due To Typographical Mistake
We have submitted Audited Financial Results (Standalone and Consolidated) for the quarter / year ended 31-03-2019, along with Auditors report and the requisite declaration on unmodified opinion post our Board meeting on 18-05-2019. In the Quick Results of Audited Financial Results (Consolidated), a minor error has crept in, on account of typographical mistake, as follows: 'Trade payables - outstanding due to creditors other than micro and small enterprises' have increased by Rs. 0.11 crore and thereby the total of current liabilities would be Rs. 20.70 crore instead of Rs. 20.59 crore as mentioned therein. The total equity and liabilities therefore would be Rs. 474.83 crore. There is no change in the Profit and EPS numbers (both standalone and consolidated) reported in our financial results already submitted. The aforesaid correction has been made in the full financial results filed today, which is also being made available on the website of the Company at www.thyrocare.com Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are forwarding copy of Press Release on Annual Results of our company for the year ended 31-03-2019. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation
We are forwarding copy of Presentation on Annual Results of our company for the year ended 31-03-2019. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company's financial results for Quarter / Full Year ended March 31, 2019, on Tuesday, May 21, 2019 at 04.00 P.M. local time. Dr. A. Velumani, Chairman, MD & CEO, Mr. A. Sundararaju, CFO, Mr. Sachin Salvi, Vice-President- Finance, and Dr. Caesar Sengupta, Vice President- Operations, will represent the Company. Dial-in details are given in the copy of enclosed Invite of M/s. Prabhudas Lilladher, who are organizing the con-call.